Geneva Capital Management LLC Acquires 3,732 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

Geneva Capital Management LLC boosted its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 2.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 191,976 shares of the medical instruments supplier’s stock after acquiring an additional 3,732 shares during the period. Geneva Capital Management LLC owned 3.55% of Mesa Laboratories worth $24,930,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its stake in shares of Mesa Laboratories by 4.5% during the 1st quarter. BNP Paribas Financial Markets now owns 7,565 shares of the medical instruments supplier’s stock worth $830,000 after buying an additional 327 shares during the last quarter. Vanguard Group Inc. lifted its position in Mesa Laboratories by 0.8% during the first quarter. Vanguard Group Inc. now owns 373,397 shares of the medical instruments supplier’s stock worth $40,973,000 after acquiring an additional 3,119 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Mesa Laboratories by 7.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 6,968 shares of the medical instruments supplier’s stock worth $761,000 after acquiring an additional 494 shares during the period. EntryPoint Capital LLC grew its position in shares of Mesa Laboratories by 35.2% in the first quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock valued at $81,000 after purchasing an additional 193 shares during the last quarter. Finally, Keeley Teton Advisors LLC bought a new position in shares of Mesa Laboratories during the first quarter worth approximately $2,606,000. Institutional investors and hedge funds own 90.60% of the company’s stock.

Analyst Upgrades and Downgrades

MLAB has been the topic of a number of research reports. Wells Fargo & Company began coverage on Mesa Laboratories in a report on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 price objective on the stock. StockNews.com lowered shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Evercore ISI raised their target price on shares of Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st.

Insider Activity

In other Mesa Laboratories news, SVP Brian David Archbold sold 1,499 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $125.00, for a total transaction of $187,375.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Gary M. Owens sold 2,518 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the completion of the transaction, the chief executive officer now directly owns 45,888 shares in the company, valued at $5,213,794.56. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian David Archbold sold 1,499 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $125.00, for a total value of $187,375.00. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Mesa Laboratories Stock Performance

Shares of Mesa Laboratories stock opened at $112.40 on Wednesday. Mesa Laboratories, Inc. has a fifty-two week low of $82.86 and a fifty-two week high of $141.17. The firm has a market capitalization of $610.44 million, a P/E ratio of -2.47 and a beta of 0.87. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. The company’s 50 day moving average price is $124.09 and its two-hundred day moving average price is $115.00.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 29th will be given a $0.16 dividend. The ex-dividend date is Friday, November 29th. This represents a $0.64 annualized dividend and a yield of 0.57%. Mesa Laboratories’s dividend payout ratio is presently -1.40%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.